Previous 10 | Next 10 |
home / stock / nvo / nvo articles
Eli Lilly (NYSE:LLY) is aggressively pursuing collaborations with outsourcing partners to ramp up the production of its obesity drug, Zepbound...
As President Joe Biden prepares for his State of the Union address on Thursday, he's expected to touch on several key issues including Bidenom...
Tuesday, Novo Nordisk A/S (NYSE:NVO) released the headline results from the kidney outcomes trial, FLOW. The trial achieved its primary e...
Tuesday, Novo Nordisk A/S (NYSE:NVO) released the headline results from the kidney outcomes trial, FLOW. The study compared inj...
CNBC host Jim Cramer advised investors to gear up for a potential market sell-off, asserting that they should be ready to make purchases if underva...
BofA Securities says Eli Lilly and Company (NYSE:LLY) remains a top choice in Biopharma analysis, boasting a remarkable year-to-date...
The World Health Organization (WHO) has cautioned that the increasing global obesity crisis, which now affects over a billion people, cannot be res...
Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 7.05% on an annualized basis producing an average annual return of 17...
Viking Therapeutics Inc (NASDAQ:VKTX) recently released top-line results from a successful Phase 2 weight loss trial. Patients receiving VK2735 d...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...
2024-07-14 05:20:00 ET Two pharma juggernauts, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) , are picking up speed in their preparations for an epic battle to control the market for weight loss drugs. The prize for the victor will be a larger market share of what may b...